NCT04838301View on ClinicalTrials.gov

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions
Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative Diseases
Interventions
DRUG

Allopregnanolone

Allopregnanolone 4mg IV via 30-minute infusion, once per week.

OTHER

Placebo

Normal saline solution IV via 30-minute infusion, once per week

Trial Locations (8)

32789

RECRUITING

Conquest Research, Winter Park

32807

RECRUITING

Combined Research, Orlando

33135

RECRUITING

Optimus U Corporation, Miami

33137

RECRUITING

Miami Jewish Health, Miami

85253

RECRUITING

Perseverance Research Center, Scottsdale

92626

RECRUITING

ATP Clinical Research, Costa Mesa

92705

RECRUITING

Syrentis Clinical Research, Santa Ana

02451

RECRUITING

MedVadis Research, Waltham

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Syneos Health

OTHER

collaborator

University of Southern California

OTHER

collaborator

ADM Diagnostics

UNKNOWN

lead

University of Arizona

OTHER